<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30294" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Stevens-Johnson Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Oakley</surname>
            <given-names>Amanda M.</given-names>
          </name>
          <aff>University of Auckland</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Krishnamurthy</surname>
            <given-names>Karthik</given-names>
          </name>
          <aff>HCA Florida Orange Park Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amanda Oakley declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Karthik Krishnamurthy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30294.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Stevens-Johnson syndrome and toxic epidermal necrolysis are acute, rare, and potentially fatal skin reactions involving loss of skin and, in some cases, mucosal membranes accompanied by systemic symptoms. Medications are causative in over 80 percent of cases. Stevens-Johnson syndrome and toxic epidermal necrolysis are distinguished based on the extent of the detached skin surface area. This activity illustrates the evaluation and treatment of Stevens-Johnson syndrome and of toxic epidermal necrolysis and reviews the role of the interprofessional team in managing those with these conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the difference between Stevens-Johnson syndrome and toxic epidermal necrolysis.</p></list-item><list-item><p>Summarize differential diagnoses of Stevens-Johnson syndrome and of toxic epidermal necrolysis.</p></list-item><list-item><p>Review the treatment options for Stevens-Johnson syndrome and toxic epidermal necrolysis.</p></list-item><list-item><p>Explain the role of interprofessional team members in optimizing collaboration and communication to ensure patients with Stevens-Johnson syndrome or toxic epidermal necrolysis receive high-quality care, which will lead to enhanced outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30294&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30294">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30294.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Previously known as Lyell syndrome, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) are variants of the same condition and are distinct from&#x000a0;erythema multiforme major staphylococcal scalded skin syndrome&#x000ad;, and other drug eruptions.<xref ref-type="bibr" rid="article-30294.r1">[1]</xref><xref ref-type="bibr" rid="article-30294.r2">[2]</xref><xref ref-type="bibr" rid="article-30294.r3">[3]</xref></p>
        <p>Stevens-Johnson&#x000a0;syndrome/toxic epidermal necrolysis is a rare, acute, serious, and potentially fatal skin reaction in which there are sheet-like skin and mucosal loss accompanied by systemic symptoms. Medications are causative in over 80% of cases.</p>
        <p>Stevens-Johnson&#x000a0;syndrome/toxic epidermal necrolysis&#x000a0;is classified by the extent of&#x000a0;the detached skin surface area.</p>
        <list list-type="bullet">
          <list-item>
            <p>Stevens-Johnson&#x000a0;syndrome: less than 10% body surface area</p>
          </list-item>
          <list-item>
            <p>Overlap&#x000a0;Stevens-Johnson&#x000a0;syndrome/toxic epidermal necrolysis: 10% to 30%&#x000a0;body surface area</p>
          </list-item>
          <list-item>
            <p>Toxic epidermal necrolysis&#x000a0;more than 30% body surface area</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30294.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Stevens-Johnson&#x000a0;syndrome/toxic epidermal necrolysis&#x000a0;is a rare and unpredictable reaction to medication&#x000a0;that involves drug-specific CD8+ cytotoxic lymphocytes, the Fas-Fas ligand (FasL) pathway of apoptosis, and granule-mediated exocytosis and tumor necrosis factor-alfa (TNF&#x02013;alpha)/death receptor pathway.&#x000a0;<xref ref-type="bibr" rid="article-30294.r4">[4]</xref><xref ref-type="bibr" rid="article-30294.r5">[5]</xref></p>
        <p>Current theories address the following mechanisms, among others.</p>
        <list list-type="bullet">
          <list-item>
            <p>Granulysin, found in the cytotoxic granules, is the main cause of keratinocyte apoptosis.</p>
          </list-item>
          <list-item>
            <p>Fas&#x02013;FasL, expressed on the activated cytotoxic T cells, can also destroy keratinocytes via the production of intracellular caspases.</p>
          </list-item>
          <list-item>
            <p>Cytotoxic T cells exocytose perforin and granzyme B, which create channels in the target cell membrane activating the caspases.</p>
          </list-item>
          <list-item>
            <p>TNF&#x02013;alpha may cause apoptosis or protect from it.</p>
          </list-item>
          <list-item>
            <p>Nitrous oxide (NO) induced by TNF&#x02013;alpha and interferon (IFN)&#x02013;alpha may stimulate caspases.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30294.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Stevens-Johnson&#x000a0;syndrome/toxic epidermal necrolysis&#x000a0;is estimated to affect two to seven per million people each year. Stevens-Johnson syndrome&#x000a0;is three times more common than toxic epidermal necrolysis.&#x000a0;Stevens-Johnson&#x000a0;syndrome/toxic epidermal necrolysis&#x000a0;can affect anyone with a genetic predisposition: any age, either sex, and all races, although it is more common in older people and women. It is much more likely to occur in people infected with the human immunodeficiency virus (HIV), with an estimated incidence of 1/1000.<xref ref-type="bibr" rid="article-30294.r6">[6]</xref><xref ref-type="bibr" rid="article-30294.r7">[7]</xref><xref ref-type="bibr" rid="article-30294.r8">[8]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Numerous medications have been reported to trigger&#x000a0;Stevens-Johnson&#x000a0;syndrome/toxic epidermal necrolysis.</p>
          </list-item>
          <list-item>
            <p>Stevens-Johnson&#x000a0;syndrome/toxic epidermal necrolysis&#x000a0;are rarely associated with vaccination and infections such as mycoplasma, cytomegalovirus, and dengue.</p>
          </list-item>
        </list>
        <p>The drugs that most commonly cause Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Anticonvulsants: lamotrigine, carbamazepine, phenytoin, phenobarbitone</p>
          </list-item>
          <list-item>
            <p>Allopurinol, especially in doses of more than 100 mg per day</p>
          </list-item>
          <list-item>
            <p>Sulfonamides: cotrimoxazole, sulfasalazine</p>
          </list-item>
          <list-item>
            <p>Antibiotics: penicillins, cephalosporins, quinolones, minocycline</p>
          </list-item>
          <list-item>
            <p>Paracetamol/acetaminophen</p>
          </list-item>
          <list-item>
            <p>Nevirapine (non-nucleoside reverse-transcriptase inhibitor)</p>
          </list-item>
          <list-item>
            <p>Nonsteroidal anti-inflammatory drugs (NSAIDs) (oxicam type mainly)</p>
          </list-item>
          <list-item>
            <p>Contrast media</p>
          </list-item>
        </list>
        <p>Genetic factors include human leukocyte antigen (<italic toggle="yes">HLA</italic>) allotypes that lead to an increased risk of Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;when exposed to aromatic anticonvulsants and allopurinol. Family members of a patient with Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;should be advised&#x000a0;that they are at risk of developing the disease and should&#x000a0;be cautious about taking any medications associated with the disease.<xref ref-type="bibr" rid="article-30294.r9">[9]</xref></p>
        <p>To date, findings have included the risk of Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;in:</p>
        <list list-type="bullet">
          <list-item>
            <p>Han Chinese, Thai, Malaysian, and South Indian people if they carry <italic toggle="yes">HLA-B*1502</italic> and take aromatic anticonvulsants.</p>
          </list-item>
          <list-item>
            <p>Han Chinese if they carry <italic toggle="yes">HLA-B*5801</italic> and take allopurinol</p>
          </list-item>
          <list-item>
            <p>Europeans if they carry <italic toggle="yes">HLA-B*5701</italic> and take abacavir, or&#x000a0;if they carry <italic toggle="yes">HLA-A*3101</italic> and take carbamazepine.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30294.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The initial step for Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;may be interaction/binding of a drug-associated antigen or metabolite with the major histocompatibility complex (MHC) type 1 or cellular peptide to form an immunogenic compound. The exact mechanism is speculative.<xref ref-type="bibr" rid="article-30294.r10">[10]</xref></p>
        <p>Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;is T&#x02013;cell-mediated.</p>
        <list list-type="bullet">
          <list-item>
            <p>CD8+ cells are present in blister fluid and may induce keratinocyte apoptosis.</p>
          </list-item>
          <list-item>
            <p>Other cells of the innate immune system play a role.</p>
          </list-item>
          <list-item>
            <p>CD40 ligand cells are also present and may induce the release of TNF&#x02013;alpha, nitrous oxide, interleukin 8 (IL-8), and cell adhesion antibodies. TNF&#x02013;alpha also induces apoptosis.</p>
          </list-item>
          <list-item>
            <p>Both Th1 and Th2 cytokines are present.</p>
          </list-item>
        </list>
        <p>Other cells implicated in Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;include macrophages, neutrophils, and natural killer (NK) cells.</p>
        <p>The pharmacologic interaction of drugs with the immune system could result in binding of the responsible drug to MHC-1 and the T cell receptor. An alternative theory is a pro-hapten concept, in which drug metabolites become immunogenic and stimulate the immune system.</p>
      </sec>
      <sec id="article-30294.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histology of the skin reveals&#x000a0;necrosis of keratinocytes, epidermal (or epithelial) necrosis, and mild lymphocytic dermal infiltration. Direct immune fluorescence is negative.</p>
      </sec>
      <sec id="article-30294.s7" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>The drugs that precipitate Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;tend to&#x000a0;have long half-lives and are nearly always taken systemically. Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;can&#x000a0;develop within a few days to eight weeks after starting a&#x000a0;new drug. A subsequent exposure can result in symptoms within a few hours.</p>
      </sec>
      <sec id="article-30294.s8" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The illness&#x000a0;begins with nonspecific symptoms such as fever and malaise, upper respiratory tract symptoms such as a cough, rhinitis, sore eyes, and myalgia. Over the next three to four days,&#x000a0;a blistering rash and erosions&#x000a0;appear on the face, trunk, limbs, and mucosal surfaces.</p>
        <list list-type="bullet">
          <list-item>
            <p>Erythematous, targetoid, annular, or purpuric macules</p>
          </list-item>
          <list-item>
            <p>Flaccid bullae</p>
          </list-item>
          <list-item>
            <p>Large painful erosions</p>
          </list-item>
          <list-item>
            <p>Nikolsky-positive (lateral pressure on the skin results in shedding of the epidermis)</p>
          </list-item>
        </list>
        <p>Early on, toxic epidermal necrolysis&#x000a0;displays widespread tender erythroderma and erosions (with or without targetoid rash), whereas Stevens-Johnson syndrome&#x000a0;is characterized more by targetoid rash, with fewer areas of denudation.</p>
        <p>Mucosal ulceration and erosions can involve lips, mouth, pharynx, esophagus and gastrointestinal tract, eyes, genitals,&#x000a0;upper respiratory tract. About half of patients have involvement of three mucosal sites.</p>
        <p>The patient is very&#x000a0;ill, anxious, and in pain. Liver, kidneys, lungs, bone marrow, and joints may be affected by Stevens-Johnson syndrome/toxic epidermal necrolysis. Typical symptoms include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Fever, malaise, headache, anorexia, pharyngitis&#x000ad;</p>
          </list-item>
          <list-item>
            <p>Symptoms due to acute dysfunction of ocular, pulmonary, cardiovascular, gastrointestinal, renal, and hematological systems.</p>
          </list-item>
        </list>
        <p>Features may overlap with other severe cutaneous adverse reactions (SCAR), such as acute generalized exanthematous pustulosis (causing subcorneal pustules) and drug hypersensitivity syndrome (causing a morbilliform eruption and involving other organs).</p>
      </sec>
      <sec id="article-30294.s9" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Investigations may include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Urgent frozen sections of skin biopsy: full-thickness skin necrosis</p>
          </list-item>
          <list-item>
            <p>Direct immune fluorescence: negative</p>
          </list-item>
          <list-item>
            <p>Complete blood count (CBC): anemia, lymphopenia, neutropenia, eosinophilia, atypical lymphocytosis</p>
          </list-item>
          <list-item>
            <p>Liver function tests (LFT): elevated transaminases, hypoalbuminemia</p>
          </list-item>
          <list-item>
            <p>Renal function: microalbuminuria, renal tubular enzymes in urine, reduced glomerular filtration, rising creatinine and urea, hyponatremia</p>
          </list-item>
          <list-item>
            <p>Pulmonary function: bronchial mucosal sloughing on bronchoscopy, interstitial infiltrates on chest x-ray</p>
          </list-item>
          <list-item>
            <p>Cardiac function: abnormal ECG and imaging.</p>
          </list-item>
        </list>
        <p>The severity of Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;is assessed using SCORTEN. One point is scored for each of the following seven&#x000a0;criteria at admission.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Age &#x000a0;older than 40 years</p>
          </list-item>
          <list-item>
            <p>Presence of a malignancy</p>
          </list-item>
          <list-item>
            <p>Heart rate of more than 120 bpm</p>
          </list-item>
          <list-item>
            <p>Initial percentage of epidermal detachment greater than 10%</p>
          </list-item>
          <list-item>
            <p>Serum urea level greater than 10 mmol/L</p>
          </list-item>
          <list-item>
            <p>Serum glucose level greater than 14 mmol/L</p>
          </list-item>
          <list-item>
            <p>Serum bicarbonate level less than 20 mmol/L</p>
          </list-item>
        </list>
        <p>The risk of dying from Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;depends on the score.&#x000a0;The mortality rate is more than 40 times higher in those with bicarbonate levels less than 20 mmol/L compared with those with higher levels. &#x000a0;A SCORTEN ranges with their associated mortality (in&#x000a0;%) are&#x000a0;as follows: score 0-1 (3.2%), score 2 (12.1%), score 3 (35.3%), score 4 (58.3%), and score 5 (&#x0003e;90%).<xref ref-type="bibr" rid="article-30294.r11">[11]</xref><xref ref-type="bibr" rid="article-30294.r12">[12]</xref></p>
        <p>In patients on multiple drugs known to cause Stevens-Johnson syndrome/toxic epidermal necrolysis, the algorithm ALDEN has been developed to determine the likely cause.</p>
        <list list-type="bullet">
          <list-item>
            <p>The period between drug intake and the onset of reaction (index day): 5 to 28 days (score of 3), 29 to 56 days (2), 1 to 4 days (1), more than 56 days (&#x02013;1), index day (&#x02013;3) for the first episode; &#x000a0;1 to 4 days (score of 3), 5 to 56 days (1) for a subsequent episode</p>
          </list-item>
          <list-item>
            <p>Presence of drug on index day or within five times elimination half-life: stopped (1), unknown (0), stopped earlier (&#x02013;1), continued beyond index day (&#x02013;2)</p>
          </list-item>
          <list-item>
            <p>Previous history of adverse reaction to the same drug: Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;(4), Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;to a similar drug (2), other reaction to same or similar drug (1), none (0), previous use without reaction (&#x02013;2)</p>
          </list-item>
          <list-item>
            <p>The notoriety of the drug, according to SCAR study: high risk (3), lower risk (2), possible&#x000a0;risk (1), under surveillance or new drug (0), no evidence of association (&#x02013;1)</p>
          </list-item>
          <list-item>
            <p>Other possible&#x000a0;cause: infection (&#x02013;1), another drug that high risk (&#x02013;1 for each other drug)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30294.s10" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Patients should undergo interprofessional assessment in a specialized hospital environment.&#x000a0;<xref ref-type="bibr" rid="article-30294.r13">[13]</xref><xref ref-type="bibr" rid="article-30294.r14">[14]</xref><xref ref-type="bibr" rid="article-30294.r15">[15]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Intensivist</p>
          </list-item>
          <list-item>
            <p>Dermatologist</p>
          </list-item>
          <list-item>
            <p>Plastic surgery or burns specialist</p>
          </list-item>
          <list-item>
            <p>Ophthalmologist</p>
          </list-item>
          <list-item>
            <p>Gynecologist</p>
          </list-item>
          <list-item>
            <p>Urologist&#x000ad;</p>
          </list-item>
          <list-item>
            <p>Respiratory physician</p>
          </list-item>
          <list-item>
            <p>Physical therapist</p>
          </list-item>
          <list-item>
            <p>Nutritionist</p>
          </list-item>
        </list>
        <p>Care of a patient with Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;requires supportive care&#x000a0;<xref ref-type="bibr" rid="article-30294.r16">[16]</xref>, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cessation of the suspected causative drug(s)</p>
          </list-item>
          <list-item>
            <p>Hospital admission: preferably to an intensive care and/or burn unit</p>
          </list-item>
          <list-item>
            <p>Fluid replacement (crystalloid)</p>
          </list-item>
          <list-item>
            <p>Nutritional assessment: may require nasogastric tube feeding</p>
          </list-item>
          <list-item>
            <p>Temperature&#x000a0;control: warm environment, emergency blanket</p>
          </list-item>
          <list-item>
            <p>Pain relief&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Supplemental oxygen and, in some cases, intubation with mechanical ventilation</p>
          </list-item>
          <list-item>
            <p>Sterile/aseptic handling</p>
          </list-item>
        </list>
        <p>Skincare requires daily examination of skin and mucosal surfaces for infection, non-adherent dressings, and avoidance of trauma to the skin. Mucosal surfaces require careful cleansing&#x000a0;and&#x000a0;topical anesthetics.</p>
        <list list-type="bullet">
          <list-item>
            <p>Gentle removal of necrotic skin/mucosal tissue</p>
          </list-item>
          <list-item>
            <p>Culture of skin lesions, axillae, and groins every two days</p>
          </list-item>
        </list>
        <p>Antibiotics may be required for secondary infection but are best avoided prophylactically.</p>
        <p>It is unknown whether&#x000a0;systemic corticosteroids are&#x000a0;beneficial, but they are often prescribed in high doses for the first three to five days of admission. Granulocyte colony-stimulating factor (G-CSF) may be of benefit in patients with severe neutropenia.</p>
        <p>Other drugs reported effective include systemic corticosteroids, ciclosporin, TNF-alpha inhibitors <xref ref-type="bibr" rid="article-30294.r17">[17]</xref>, N-acetylcysteine, and intravenous immunoglobulins. Their role remains controversial.</p>
      </sec>
      <sec id="article-30294.s11" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Other acute exfoliative conditions that may need consideration include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Other severe cutaneous adverse&#x000a0;reactions (SCAR) to drugs, such as drug hypersensitivity syndrome (DHS), acute generalized exanthematous pustulosis (AGEP)</p>
          </list-item>
          <list-item>
            <p>Other forms of drug eruption</p>
          </list-item>
          <list-item>
            <p>Erythema multiforme (EM) major</p>
          </list-item>
          <list-item>
            <p>Staphylococcal scalded skin syndrome</p>
          </list-item>
          <list-item>
            <p>Pemphigus vulgaris and pemphigus foliaceus</p>
          </list-item>
          <list-item>
            <p>Acute graft versus host disease.<xref ref-type="bibr" rid="article-30294.r18">[18]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30294.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Stevens-Johnson&#x000a0;syndrome/toxic epidermal necrolysis is potentially very serious with high mortality, predicted by the extent and severity at presentation (see SCORTEN and ALDEN above).&#x000a0;</p>
        <p>Mean adjusted&#x000a0;mortality reported for the Nationwide Inpatient Sample 2009-2012&#x000a0;(US) was 4.8% for SJS, 19.4% for SJS/TEN overlap, and 14.8% for TEN.<xref ref-type="bibr" rid="article-30294.r19">[19]</xref></p>
        <p>In&#x000a0;Cr&#x000e9;teil, France, 66 of 361 patients diagnosed with Stevens-Johnson&#x000a0;syndrome/toxic epidermal necrolysis&#x000a0;died (18%):&#x000a0;2% with SJS,&#x000a0;12% with SJS/TEN overlap, and&#x000a0;26% with TEN.<xref ref-type="bibr" rid="article-30294.r20">[20]</xref>&#x000a0;There has been a trend towards improved mortality in recent years, attributed mainly to better supportive care than in earlier decades.</p>
      </sec>
      <sec id="article-30294.s13" sec-type="Complications">
        <title>Complications</title>
        <p>In the acute phase, sepsis is the most common&#x000a0;serious risk of Stevens-Johnson&#x000a0;syndrome/toxic epidermal necrolysis. Organ failure may occur,&#x000a0;including pulmonary, hepatic, and renal systems.&#x000a0;</p>
        <p>The most common long-term complications of Stevens-Johnson&#x000a0;syndrome/toxic epidermal necrolysis are ocular (including blindness), cutaneous (pigmentary changes and scarring),&#x000a0;and renal. Mucosal involvement with blisters&#x000a0;and erosions&#x000a0;can lead to strictures and scarring.<xref ref-type="bibr" rid="article-30294.r21">[21]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-30294.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>The care of patients with&#x000a0;Stevens-Johnson&#x000a0;syndrome/toxic epidermal necrolysis is multidisciplinary. Patients&#x000a0;with blistering involving greater than 10% of the skin surface are usually admitted to intensive care units or burns units for supportive care.</p>
      </sec>
      <sec id="article-30294.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Death is mainly due to sepsis and multiorgan failure. Contributing causes are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastrointestinal bleeding</p>
          </list-item>
          <list-item>
            <p>Pulmonary embolism</p>
          </list-item>
          <list-item>
            <p>Myocardial infarction and pulmonary edema</p>
          </list-item>
        </list>
        <p>People who have survived Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;must avoid the causative drug or structurally related medicines as Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;may recur. Cross-reactions can occur between:</p>
        <list list-type="bullet">
          <list-item>
            <p>Anticonvulsants carbamazepine, phenytoin, lamotrigine and phenobarbital</p>
          </list-item>
          <list-item>
            <p>Beta-lactam antibiotics penicillin, cephalosporin, and carbapenem</p>
          </list-item>
          <list-item>
            <p>Nonsteroidal anti-inflammatory drugs</p>
          </list-item>
          <list-item>
            <p>Sulfonamides sulfamethoxazole, sulfadiazine, sulfapyridine</p>
          </list-item>
        </list>
        <p>Stevens-Johnson syndrome/toxic epidermal necrolysis&#x000a0;survivors may have scarring. Severe consequences can include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Ocular sequelae: dry eye, photophobia, pain, symblepharon, corneal scarring or neovascularization, trichiasis, reduced visual acuity, and blindness</p>
          </list-item>
          <list-item>
            <p>Cutaneous scarring, depigmentation, development of new melanocytic nevi, and pruritus</p>
          </list-item>
          <list-item>
            <p>Nail dystrophy, onycholysis, and loss of nails (this may recover over time)</p>
          </list-item>
          <list-item>
            <p>Diffuse scalp hair thinning</p>
          </list-item>
          <list-item>
            <p>Oral complications: discomfort, dry mouth, periodontal disease, gingival inflammation, synechiae</p>
          </list-item>
          <list-item>
            <p>Esophageal strictures</p>
          </list-item>
          <list-item>
            <p>Vulvovaginal stenosis or occlusion in females and phimosis in males</p>
          </list-item>
          <list-item>
            <p>Persistent pulmonary disease: bronchitis, bronchiectasis, bronchiolitis obliterans, organizing pneumonia, respiratory tract obstruction</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30294.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of SJS is interprofessional. A number of specialists are usually involved in the care of these patients, including a dermatologist, intensivist, ophthalmologist, pulmonologist, nephrologist, plastic surgeon, and gastroenterologist, functioning as an interprofessional team. The acute care of these patients is provided by wound care. Critical care nurses provide much of the hands-on care. The pharmacist must also closely assess the medications that the patient is receiving to prevent exacerbation of the disorder or determine if any of the patient's medications could be the trigger for the condition. Even after treatment, these patients may have severe cosmetic deficits and may require mental health counseling. If the lesions occur across joints, the patient may benefit from physical therapy to restore function and muscle strength. The patient has to be educated on the use of ocular lubricants because of the sicca-like syndrome. Many patients lose weight after suffering a severe reaction and should be referred to a dietitian. Following discharge, the patients need long-term follow-up to ensure that there are no functional deficits, including vision loss. Once a patient has suffered an SJS, it is highly recommended that the patient wear a warning bracelet indicating the toxic agent or allergen.<xref ref-type="bibr" rid="article-30294.r22">[22]</xref><xref ref-type="bibr" rid="article-30294.r16">[16]</xref>&#x000a0;[Level 5]</p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>The outcomes of patients with SJS depend on the extent and severity of skin involvement. For those with a mild eruption, the lesions usually heal in 12&#x000a0;to 16 weeks. Mild scarring may occur, but there is usually no functional loss unless the eyes and other mucous membranes are involved. When the involved skin area is more than 20%, mortality rates of 1 to 27% have been reported. The presence of concomitant bacterial infection can increase mortality rates. Factors that adversely affect the outcome include advanced age, leucopenia, presence of a malignancy, renal dysfunction, hyperglycemia, and more than 10% BSA involvement. Survivors of SJS may develop inverted eyelids, sicca-like syndrome, visual loss, and corneal neovascularization, but an interprofessional approach will lead to better outcomes.<xref ref-type="bibr" rid="article-30294.r23">[23]</xref><xref ref-type="bibr" rid="article-30294.r24">[24]</xref> [Level 5]</p>
      </sec>
      <sec id="article-30294.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30294&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30294">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/stevens-johnson-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30294">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30294/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30294">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-30294.s18">
        <fig id="article-30294.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Erythematous, Purpuric, Macules, targetoid lesions, Stevens Johnson Syndrome <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sjs-ten-3" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-30294.s19">
        <fig id="article-30294.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Widespread early morbilliform eruption with flaccid bullae in patient with toxic epidermal necrolysis <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dermnetnz.org/images">DermNet New Zealand</ext-link></p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="sjs-ten-4" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-30294.s20">
        <fig id="article-30294.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Healing Toxic epidermal necrolysis Contributed by Dr. Shyam Verma, MBBS, DVD, FRCP, FAAD, Vadodara, India</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="healing__toxic__epidermal__necrolysis__SV" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-30294.s21">
        <title>References</title>
        <ref id="article-30294.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jha</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kanish</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Badyal</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>A Study of Cutaneous Adverse Drug Reactions in a Tertiary Care Center in Punjab.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2018</year>
            <season>Sep-Oct</season>
            <volume>9</volume>
            <issue>5</issue>
            <fpage>299</fpage>
            <page-range>299-303</page-range>
            <pub-id pub-id-type="pmid">30258795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Auyeung</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Successful Treatment of Stevens-Johnson Syndrome with Cyclosporine and Corticosteroid.</article-title>
            <source>Can J Hosp Pharm</source>
            <year>2018</year>
            <season>Jul-Aug</season>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>272</fpage>
            <page-range>272-275</page-range>
            <pub-id pub-id-type="pmid">30186001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ravindran</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rishi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rishi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Krishnamoorthy</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Boston Type 2 keratoprosthesis- mid term outcomes from a tertiary eye care centre in India.</article-title>
            <source>Ocul Surf</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>50</fpage>
            <page-range>50-54</page-range>
            <pub-id pub-id-type="pmid">30157458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frey</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bodmer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bircher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jick</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Meier</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Spoendlin</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study.</article-title>
            <source>Drug Saf</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-66</page-range>
            <pub-id pub-id-type="pmid">30112729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kanbe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tamaki</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Furuichi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Uejima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suganuma</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Takano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kawano</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis.</article-title>
            <source>Pediatr Int</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>60</volume>
            <issue>8</issue>
            <fpage>697</fpage>
            <page-range>697-702</page-range>
            <pub-id pub-id-type="pmid">29888432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Corrigendum to "The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China".</article-title>
            <source>J Immunol Res</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>4154507</fpage>
            <pub-id pub-id-type="pmid">30050956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velasco-Tirado</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Alonso-Sard&#x000f3;n</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cosano-Quero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Romero-Alegr&#x000ed;a</surname>
                <given-names>&#x000c1;</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez-Los Arcos</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Bernus</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pardo-Lled&#x000ed;as</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Belhassen-Garc&#x000ed;a</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Life-threatening dermatoses: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Impact on the Spanish public health system (2010-2015).</article-title>
            <source>PLoS One</source>
            <year>2018</year>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>e0198582</fpage>
            <pub-id pub-id-type="pmid">29912947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Safiri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ashrafi-Asgarabad</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptic drugs: Comment on data sparsity.</article-title>
            <source>Epilepsia</source>
            <year>2018</year>
            <month>May</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>1083</fpage>
            <page-range>1083-1084</page-range>
            <pub-id pub-id-type="pmid">29723404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolf</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marinovi&#x00107;</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Drug eruptions in the mature patient.</article-title>
            <source>Clin Dermatol</source>
            <year>2018</year>
            <season>Mar-Apr</season>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>249</fpage>
            <page-range>249-254</page-range>
            <pub-id pub-id-type="pmid">29566929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tangamornsuksan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lohitnavy</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Association Between HLA-B*1301 and Dapsone-Induced Cutaneous Adverse Drug Reactions: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Dermatol</source>
            <year>2018</year>
            <month>Apr</month>
            <day>01</day>
            <volume>154</volume>
            <issue>4</issue>
            <fpage>441</fpage>
            <page-range>441-446</page-range>
            <pub-id pub-id-type="pmid">29541744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richard</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Hamer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Musso</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Short</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>O'Neal</surname>
                <given-names>HR</given-names>
              </name>
            </person-group>
            <article-title>Variability in Management of Patients With SJS/TEN: A Survey of Burn Unit Directors.</article-title>
            <source>J Burn Care Res</source>
            <year>2018</year>
            <month>Jun</month>
            <day>13</day>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>585</fpage>
            <page-range>585-592</page-range>
            <pub-id pub-id-type="pmid">29901804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortonne</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>[Histopathology of cutaneous drug reactions].</article-title>
            <source>Ann Pathol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-19</page-range>
            <pub-id pub-id-type="pmid">29279184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Plachouri</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Vryzaki</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Georgiou</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.</article-title>
            <source>Curr Drug Saf</source>
            <year>2019</year>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-20</page-range>
            <pub-id pub-id-type="pmid">30058498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lerma</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Mac&#x000ed;as</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moscoso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hern&#x000e1;ndez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>de Abajo</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Care in patients with epidermal necrolysis in burn units. A nursing perspective.</article-title>
            <source>Burns</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>44</volume>
            <issue>8</issue>
            <fpage>1962</fpage>
            <page-range>1962-1972</page-range>
            <pub-id pub-id-type="pmid">30005991</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Das</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Management of Stevens-Johnson Syndrome-Toxic Epidermal Necrolysis: Looking Beyond Guidelines!</article-title>
            <source>Indian J Dermatol</source>
            <year>2018</year>
            <season>Mar-Apr</season>
            <volume>63</volume>
            <issue>2</issue>
            <fpage>117</fpage>
            <page-range>117-124</page-range>
            <pub-id pub-id-type="pmid">29692452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneider</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.</article-title>
            <source>Adv Ther</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>1235</fpage>
            <page-range>1235-1244</page-range>
            <pub-id pub-id-type="pmid">28439852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>66</fpage>
            <page-range>66-73</page-range>
            <pub-id pub-id-type="pmid">30702955</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>McDonough</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>BW</given-names>
              </name>
            </person-group>
            <article-title>Toxic epidermal necrolysis: Part II. Prognosis, sequelae, diagnosis, differential diagnosis, prevention, and treatment.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>187.e1</fpage>
            <page-range>187.e1-16; quiz 203-4</page-range>
            <pub-id pub-id-type="pmid">23866879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hsu</surname>
                <given-names>DY</given-names>
              </name>
              <name>
                <surname>Brieva</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Silverberg</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Silverberg</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults.</article-title>
            <source>J Invest Dermatol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>136</volume>
            <issue>7</issue>
            <fpage>1387</fpage>
            <page-range>1387-1397</page-range>
            <pub-id pub-id-type="pmid">27039263</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bettuzzi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Penso</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>de Prost</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hemery</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Colin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mekontso-Dessap</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fardet</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chosidow</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Wolkenstein</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sbidian</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ingen-Housz-Oro</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Trends in mortality rates for Stevens-Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017.</article-title>
            <source>Br J Dermatol</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>182</volume>
            <issue>1</issue>
            <fpage>247</fpage>
            <page-range>247-248</page-range>
            <pub-id pub-id-type="pmid">31323695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lerch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mainetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Terziroli Beretta-Piccoli</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Harr</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>147</fpage>
            <page-range>147-176</page-range>
            <pub-id pub-id-type="pmid">29188475</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sikora</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kirchhof</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Miliszewski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dutz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.</article-title>
            <source>Burns</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>807</fpage>
            <page-range>807-815</page-range>
            <pub-id pub-id-type="pmid">29627131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antoon</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>244</fpage>
            <page-range>244-250.e1</page-range>
            <pub-id pub-id-type="pmid">29859332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30294.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antoon</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Incidence, outcomes, and resource use in children with Stevens-Johnson syndrome and toxic epidermal necrolysis.</article-title>
            <source>Pediatr Dermatol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>35</volume>
            <issue>2</issue>
            <fpage>182</fpage>
            <page-range>182-187</page-range>
            <pub-id pub-id-type="pmid">29315761</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
